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ABSTRACT 
 
Background: 
Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease 
affecting people of various ages across the globe.  Treatment for the disease is 
in the form of immunosuppressive drugs.  Due to either the treatment of the 
disease or the disease itself, SLE patients have been shown to have abnormal 
immune function.  This dysfunction accounts for an increased rate of infections in 
this population.   
 
Reactivation of the varicella zoster virus (VZV), herpes zoster (HZ), has been 
shown to occur in the SLE population at higher rates than the general, healthy 
population.  Recently a vaccine for HZ was approved by the Food and Drug 
Administration for individuals 50 years of age and older.   
 
  v 
Study: 
In this study we examined the safety and immunogenicity of the HZ vaccine, 
Zostavax, in a small sample of SLE patients.  This study was a case-control with 
a ratio of 1:1, SLE patients to healthy controls.  The total sample size was 20 with 
an average age of 57.9.  All study participants were seen in a clinical setting at 
the Oklahoma Medical Research Foundation and signed informed consents.  
Subjects were seen for an initial baseline visit, and were administered the 
vaccine.   Follow-up visits were scheduled at 2, 6 and 12 weeks.  
 
Results: 
The notable finding of this study is a lack of significant differences between SLE 
patients and healthy individuals with one exception.   At the 6-week point a 
significant difference was found (P=0.03) between SLE patients and healthy 
controls, with regards to the number of VZV-specific cells stimulated to produce 
interferon gamma.  No vaccine-induced illness was evident and there was no 
sign of an increase in SLE disease activity in patients.  
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INTRODUCTION 
Systemic Lupus Erythematosus  
Systemic Lupus Erythematosus (SLE) is a chronic multi-system 
autoimmune disease characterized by chronic inflammation, auto anti-body 
production and complement-fixing immune complexes with disease activity that 
waxes and wanes.  Prior to the advent and use of immunosuppressive drugs, 
SLE was almost uniformly fatal, and even now with current immunosuppressive 
therapy some SLE patients still develop life-threatening manifestations. While 
any organ of the body is susceptible to inflammation and damage including the 
lungs, central nervous system (CNS), blood vessels, and gastrointestinal tract, 
the renal, musculoskeletal and cutaneous systems are especially at risk.  The 
most common denominator of all SLE patients is the presence of anti-nuclear 
antibodies (ANAs), which is necessary but not sufficient for diagnosis.  The 
presentation and age of SLE onset is variable, but many women present during 
their childbearing years [1].  
 Reports vary concerning the number of people affected by SLE, ranging 
from 161,000 to 322,000  in the U.S. alone, and the number is likely to increase 
due to new criteria for diagnosis by the American College of Rheumatology 
(ACR) [2] [3].  Women represent 90% of the adult SLE population and are 10 times 
more likely to develop SLE compared to men [4].  Juvenile SLE is less prevalent 
than adult SLE; it affects between 5,000 and 10,000 individuals in the U.S., with 
a more equal male to female ratio, 40 and 60% respectively [5].     
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Herpes Zoster 
Shingles, or herpes zoster (HZ), is a reactivation of the varicella virus that 
causes chickenpox during primary infection. Once primary infection with varicella 
resolves, the virus becomes dormant in sensory ganglia awaiting potential 
reactivation; this typically happens decades after initial infection and in some 
cases never.  As of 2003, 500,000 people in the United States had annual 
reoccurrence of HZ, and in 2011 more than 1 million cases were seen in the 
United States alone [6].  HZ usually presents late in life and is characterized by a 
very painful rash usually confined to one dermatome.  The pain usually subsides 
as the rash heals, but on occasion the pain persists for weeks to months 
afterwards, and is known as post-herpetic neuralgia (PHN).  HZ reactivation in 
the general population occurs with a prevalence of 20-30% and increases with 
age.  Also with age, the risk and severity of PHN increases as well.  Over 50% of 
individuals age 85 and above are affected by shingles [6].   
The Zostavax vaccine, has been approved for the prevention of shingles 
by the Food and Drug Administration, for use by healthy adults 50 years and 
older, and the Center for Disease Control and Prevention recommends the 
vaccine for those 60 years and older.  Yet the vaccine has not been approved for 
use by those who are immunosuppressed, such as SLE patients, who may have 
a relatively high risk for developing HZ, and to date no published data is available 
to quantify the safety or efficacy of the Zostavax vaccine in SLE patients. 
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Rates of viral infections in SLE vs Healthy  
Table 1 shows all of the studies that report incidence or prevelance rates 
of HZ in SLE populations. Dates of the studies range from 1977 to 2008 and 
sample different parts of the globe.  SLE patients are at a higher risk for the 
reactivation of zoster, when compared to the general public and when compared 
to patients with other rheumatic diseases [7] [8] [9] [10].  The reported incidence rates 
of HZ in the adult SLE populations range from 6.4 cases (per 1000 patient 
years(py)) to 91.4 cases per 1000 py, with prevalence rates ranging from 4.45% 
to 46.6% respectively.  The average age of adult SLE patients who developed 
HZ in these studies ranges from 31.1 to 51.1, with the majority age at reactivation 
in the 4th decade [7] [11] [12] [13] [14] [15]. 
 
  
Table 1.  Incidence and Prevalence of Zoster in SLE Patients  
Incidence given in cases/1000 py.  (Range)  +_ Standard Deviation 
 
Author 
 
Years of 
Study 
 
Country of 
Study 
 
Sample 
Size 
 
Prevalence in 
SLE Patients 
 
Incidence in 
SLE Patients 
 
Average Age at 
HZ Diagnosis 
Retrospective 
Reviews 
 
 
     
Wang 
[11]
 1975-1981 Malaysia 184 13% N/A 34.6 (14-35) 
Manzi 
[16]
 1979-1989 United States 321 15% N/A N/A 
Nagasawa 
[7]
 1979-1989 Japan 92 43% 91.4 36.8 (19-68) 
Sayeeda 
[12]
 1982-2006 Saudi Arabia 624 5.1% N/A 31.4 (11-60) 
Lee 
[17]
 1988-2004 China 49 30.6% 58.7 14 (9.8-22.3) 
Kang 
[13]
 1990-2000 Korea 303 13.9% 32.5 34.1 +_ 11.6 
Chen, H-H 
[14]
 1996-2006 Taiwan 10,337 N/A 37.7 34.8 +_14.3 
Borba 
[15]
 1999-2006 Brazil 1,145 4.45% 6.4 39 +_13.7 
Wu 
[18]
 1999-2008 Taiwan 82 37.7% N/A 14.5 +_3.11 
Hata, A 
[10]
 2001-2007 Japan 1,077 N/A 53.7 51.18 +_20.88 
Case Control 
 Studies 
      
Moutsopoulos 
[19]
 
1978 Greece 83 21% N/A N/A 
Strom 
[20]
 1985-1987 United States 195 9.2% N/A N/A 
Khal 
[21]
 1994 United States 348 13.5% 16 N/A 
Ishikawa, O. 
[8]
 1999 Japan 58 46.6% N/A 40.2 +_13.4 
Pope, J 
[22]
 2004 United 
Kingdom 
61 19% N/A 49 +_ 2 
 
4
 
4
 
                          5 
 
The largest sample size studied to date is Chen’s investigation, reporting 
an incidence rate of 58.7 cases/1000 py with a mean age of 34 (SD +-14.3), 
among SLE patients in China, compared to an incidence of 5.1/1000 py in a 
matched control population of 62,022 [14].  The incidence of HZ by age in the 
patient population did not follow a standard distribution, skewing instead to the 
right with 66% of episodes manifesting in younger patients between the ages of 
18 and 44.  Relative risk for the reactivation of HZ in an adult SLE patient was 
also reported as an increase of four-fold over the age matched control subjects 
[14] [22].  This is in contrast to the epidemiology of HZ in the general population, 
where increasing age is among the greatest risk factors for HZ.  
Fewer reports regarding the incidence of HZ in the juvenile SLE 
population have been documented.  The results of these studies, while small in 
sample size, are far more consistent with each other than the reports of the adult 
population.  The small age range (3yrs-18yrs) that defines this population may 
account for the very similar average age of incidence, but does not explain the 
similarity in the increase in prevalence.  Within these populations the average 
age at HZ reactivation ranged between 14 and 14.5 years and the prevalence 
ranged between 30.6 % and 37.7%.   According to the Lee study, juvenile onset 
SLE was found to increase the risk of varicella zoster virus (VZV) reactivation by 
forty-fold when compared to healthy controls [17].   
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In 2011 Chen reported a higher increase of juvenile HZ in SLE patients 
when he examined age specific incidence rates [14].  The highest incidence rate 
(IR) reported in Chen’s study belonged to the youngest age-specific group and 
had an IR of 58.1 cases/1000py compared to an IR of 2.2 cases/1000py in 
healthy children matched for age.  Table 2 shows the reported IRs in the Chen 
study in Taiwan and comparative U.S. IRs as age-specific rates with and without 
SLE. 
 
 
 
 
 
Table 2.  Age-Specific rates of Incidence; Zoster in Controls and SLE Patients  
All incidences are listed as cases/1000py.     
 
Controls 
 
Age 
 
U.S. 
[23]
  
Controls 
 
Age 
 
Taiwan 
[14]
  
 
U.S. 
[24]
 
SLE 
Age 
 
Taiwan 
[14]
  
0-14 1.1 0-18 2.2  0-18 58.1 
15-29 1.4 18-24 3.2  18-24 37.5 
30-39 2.0 25-34 2.9  25-34 30 
40-49 2.9 35-44 4.8 2.1 35-44 37.7 
50-59 4.6 45-54 10.1 3.6 45-54 42.5 
60-69 6.9 55-64 10 5.8 55-64 34.1 
70-79 
80+ 
9.5 
10.9 
65 + 
75+ 
12.8 
 
6.5 
9.1 
65 + 
 
46.9 
   
 
 
 
Lee and Wu reported a decreased rate of incidence of PHN in juvenile 
studies, yet both studies report higher than normal prevalence rates of zoster 
recurrence ranging between 13.3 and 20% [17].  Recurrent HZ in the general 
population is estimated to occur in 1.4 - 6% of individuals [25] [26]. 
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A few studies reported IRs of HZ among the collective SLE population.  
The age of the subjects ranged from 11 to 60 years [11] [12]. The prevalence of HZ 
among  these studies were 5.1% and 13%, respectively [12] [11].  Contrast this with 
the reported incidence and prevalence rates of HZ in SLE patients; the average 
IR among the general population ranges from 2.58 to 4.89 (cases/1000py) as 
seen in Table 3 [14].  Interestingly, comparably immunosuppressed patients, such 
as HIV, transplantation and other rheumatic patients using the same treatments, 
run higher risks of developing multiple dermatomal HZ or disseminated HZ than 
SLE, but have a lower risk of HZ reactivation overall when compared to SLE 
patients [27].   
Overall, immunocompromised patients are also more likely to be 
hospitalized than an immunocompetent individuals.  One retrospective study 
found the prevalence of hospitalization in immunosuppressed and healthy 
controls to be 11.0% and .08% respectively [28].  This may be due to more severe 
disease or more caution on the part of the treating physicians.  However the 
severity of HZ in SLE patients has been reported as ranging from relatively 
benign with rare episodes of dissemination (by the majority) to severe with 
increased risks of dissemination [29] [16] [21].  In either case, once zoster is 
reactivated in SLE patients, further complications are likely to occur; 
superimposed bacterial infections have been reported with prevalence rates of 
9%, 11.7% and 47.7% [21] [17] [15].  With prevalence rates ranging from 4.3 to 
19.6%, PHN was reported as less frequent than subsequent infections yet it 
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causes a significant decrease in quality-adjusted life years (QALY) when it 
occurs [21] [15]. 
 
 
 
Table 3.  Incidence of Zoster in General Population (includes all ages and all health states) 
Incidence rates given as cases/1000py.  Note: 2.58, 3.48 and 3.15, 3.82; incidence rates for 
respective years. 
 
 
 
# Author Years of 
Study 
Country of 
Study 
Incidence in 
General 
Population 
1 Brisson 
[30]
 1979-1997 Canada 2.58, 3.48 
   United Kingdom 3.15, 3.82 
2 Insinga 
[23]
 2000-2001 United States 3.2 
3 Jih 
[31]
 2000-2006 Taiwan 4.89 
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Role of humoral vs CMI; VZV reactivation 
When first infected by a novel virus, the innate (non antigen(Ag)-specific) 
immune system detects viral particles and causes antiviral cytokines to be 
released by natural killer cells (NK) and cytotoxic T cells (Tc).  The cytokines 
then activate NK and Tc cells to lyse infected cells and produce interferon(IFN)-
gamma, which in turn causes the clonal expansion of Ag-specific T cells, and the 
beginning of an adaptive response.  Activated T cells trigger B cells , which then 
undergo clonial expansion producing memory B cells and virus-specific Ab-
producing plasma cells.  The final outcome of the adaptive immune response is 
the production of virus-specific memory B cells and plasma cells capable of 
expanding and producing virus-specific antibodies, clearing the infection and 
priming the immune system to prevent a second infection. 
VZV has found a way to evade clearance from the body. When an 
individual is first infected with VZV all of the same virally-activated immune 
mechanisms are initiated.  But the varicella virus has been proven to delay the 
presentation of signaling molecules important in both the innate immune 
response and the humoral immune response.  Abendroth et al (2000) did 
consecutive studies demonstrating a decrease in Major Histocompatibility (MHC) 
Class I and MHC class II molecules on cell surfaces due to VZV infection [32] [33].  
It was found that VZV inhibits IFN-gamma release, leading to a decrease in MHC 
class II presentation [32].  The authors also found that VZV initiated the retention 
of MCH class I molecules in the golgi apparatus [33].  Further evidence of this 
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delayed immune response is described by Arvin; during primary infection of VZV, 
VZV-specific T cells only just begin to be detectable a couple of days after the 
initial varicella rash is seen, which is well after the initial infection has ocurred [34].  
While there is no evidence to date, it is thought that during this interval in immune 
response, VZV may be able to inhabit, infect and become dormant in the body of 
the sensory ganglia. 
Once the acute varicella infection, “Chickenpox”, has resolved, the virus 
remains latent in the body of sensory ganglia; no longer obligated to 
circumnavigate the body’s first line of defense, it is able to infect the body once 
again through endogenous reactivation. This is unlike influenza and other viruses 
with an exogenous route of infection that are completely cleared with resolution 
of clinical manifestations. It is likely that the humoral immune response is 
responsible for the prevention of a second acute primary infection of 
“Chickenpox” while the cell-mediated immune (CMI) response is responsible for 
containing the virus within the sensory ganglia and preventing the reactivation of 
zoster [35]. 
Supporting evidence shows that reactivation, severity and possible 
complications of varicella are independent of serum Ab levels. Arvin describes 
the importance of CMI in the reactivation of VZV, and points out that the 
magnitude of Ab production does not correlate with the severity of the varicella 
infection in healthy or immunodeficient children [36].  Evidence has shown the 
insignificance of the humoral response in children with B cell deficiencies: a lack 
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of increased varicella severity in children with B cell deficiencies, who do not 
produce a full Ab repertoire [36].  Oxman demonstrated both the triviality of the 
humoral response and the importance of the CMI response by evaluating Ab 
levels against HZ incidence in an elderly population. He found Ab levels 
remained high despite an increase in incidence of zoster [37] [38].  Further 
evidence of the importance of T cell-mediated immunity to VZV reactivation was 
observed in bone marrow transplant patients (BMT).  Patients who had 
undergone T-cell depletion had an increase in incidence of zoster: 18% of the 
BMT patients had a VZV reactivation, 86% were within 18 months and 32% were 
disseminated or visceral zoster [39] [40].  Nagasawa found a similar result in the 
SLE population.  Individuals with high Ab titers were no more protected against 
VZV reactivation than those with low titers [7].   In Nagasawa’s study SLE patients 
with a history of zoster had higher Ab titers compared to healthy controls, and yet 
were still at an increased risk for VZV reactivation.  CMI was tested by Nagasawa 
in the above-mentioned SLE sample with high VZV-specific titers.  This group, 
when tested by delayed-reaction skin tests, had a postive CMI reaction only 30% 
of the time, while all of the healthy control group had a positive reaction.  Further 
statistical analysis showed a direct correlation between the result of the delayed 
skin reaction test and the ratio of VZV specific CD4+/CD8+ T cells [7].  This tells 
us that a decrease in the CD4+/CD8+ ratio might account for the decrease in 
CMI that is seen in SLE patients with regard to VZV reactivation.  Related 
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evidence supporting the necessity of VZV-specific T cells for the prevention of 
VZV dissemination was also seen in children with T cell deficiencies [35].   
Together, these data suggest that the increase in VZV reactivation seen 
within the SLE population is likely due to a decrease in CMI response.  Myimoto 
showed decreased levels of immune cells, specifically B and T (both, CD4+ and 
CD8+) cells in SLE patients when compared to healthy controls [41].  Crispin 
found a decrease in CD4+ cells bearing CD25 molecules in SLE patients with 
active disease [42].  Thus the vulnerability of a patient and the effectiveness of the 
zoster vaccine, Zostavax, may be better determined by the level of the CMI 
response.  
With the exception of Zostavax, all vaccines to date are used to prevent 
diseases caused by exogenous organisms.  Sickness due to these microbes can 
be prevented by a primed humoral immune response.  Thus vaccine 
effectiveness can be measured by the increase in numbers of antibodies, or a 
minimum value assigned to an Ab-specific titer.  Since zoster reactivation is from 
endogenous stores, a primed humoral immune response has little effect; 
reactivaion is prevented by VZV-specific T cells of the CMI system  [34].  Yet 
many of the zoster studies have analyzed the effectiveness of Zostavax by 
looking at Ab levels or recruitable cell counts.   In order to assess the 
effectivness of Zostavax in preventing the reactivation of zoster, CMI must be 
measured and considered instead of Ab production. 
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Zostavax Vaccine:   
The zostavax vaccine contains 14 times the number of plaque-forming 
units (PFU) as the varicella vaccine, but is the same attenuated Oka strain of 
VZV.  In varicella vaccine studies, higher PFUs of the primary varicella vaccine 
did not result in higher frequencies of adverse reactions and fewer adverse 
reactions were reported in association with booster vaccines [43] [44]. Since the 
zoster vaccine is technically a booster, it is likely that there would not be an 
increase in adverse reactions. 
  Further, the Oka vaccine strain of VZV has been proven susceptible to 
antivirals (acyclovir, vidarabine, BvaraU and peniclovir) at very small doses and 
has been shown to have a significantly reduced replication rate when compared 
to wild-type strains [45] [46].  This implies that if the Oka strain of VZV were to 
induce a vaccine-related disease, it would be more easily treated and less severe 
compared to a wild-type VZV strain.  It also implies that, due to the decrease in 
the replication rate, it may be safe for use in immunosuppressed individuals.   
  Like a natural infection of varicella, both humoral and cell-mediated 
responses are stimulated by the VZV vaccine. Yet, an important immunological 
difference between the vaccine strain of VZV (Oka) and the wild-type VZV exists 
[47].  The attenuated vaccine strain allows cellular production of signaling 
molecules that bridge the gap between the innate and adaptive immune 
responses, while the virulent strains interfere with this process.  Even though this 
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difference exists, measures of CMI show the vaccine to have a protective half-life 
of 56 months in healthy individuals [48].   
The zoster vaccine has shown more vigorous immune responses in 
younger individuals, and, as shown in Figure 1, demonstrates an increase in 
effectiveness in younger individuals as well [49] [50].  A negative correlation is 
shown between the age of administration of Zostavax and the reduction in risk 
associated with the reactivation of HZ [50].  The younger the patient, the greater 
the reduction [50].  As well as decreasing the risk of reactivation of HZ, the 
vaccine also decreases the severity of HZ and subsequently decreases the risk 
of developing PHN by about 66% [51] [52].   Future studies should be done to 
determine if the vaccination of even younger individuals with Zostavax is still 
further effective.    
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The live attenuated VZV vaccine has been tested in millions of healthy 
individuals and hundreds of immunosuppressed individuals, with very few serious 
complications reported.  Listed in Table 4, are case reports of individuals who 
received either the varicella or zoster vaccine and subsequently had an adverse 
reaction.  All of the individuals that presented with varicella/zoster like reactions 
were treated with antivirals and made full recoveries.   
Figure 1. Reduction rates in percentages are as follows:18% 80 years 
and up, 41% 70-79 years of age, 64% 60-69 years of age, and 70% 50-59 
years of age 
[50]
. The highest reduction was in the youngest group 
[50]
. 
Decrease in HZ Reactivation as Affected by Age at 
Vaccination 
                          16 
 
Table 4.  Case Studies of Immunosuppressed Individuals with VZV Episode/Complications 
The disease category lists underlying diseases.  Post-vaccine onset represents the number of 
days after vaccination when illness occurred.  Duration is the length of illness.  Outcome gives 
both the severity of illness and the final outcome.    
    
Author, year Disease Vaccine Post-
vaccine 
onset 
Duration Outcome 
Solid Organ  
Transplant 
     
1.   Levitsky, 
2002 [53] 
Liver 
Transplant 
Varivax 27 8 days,  
6 days 
2 bouts of cutaneous 
chicken-pox, full 
recovery 
2.   Kraft,  
2006 [54] 
Cardiac 
Transplant 
Varivax 24 10 days widespread rash, no 
systemic involvement, 
recovered 
HIV      
3.   Kramer, 
2001 [55] 
AIDS Varivax 53 39 days Disseminated 
varicella, full recovery 
Malignancies      
4.   Schrauder, 
2007 [56] 
ALL Varivax 32 10 days Died of ARDS and 
multi organ failure 
5.   Curtis, 
2008 [57] 
Breast 
Cancer 
Zostavax 8 0 days Mildly painful rash, 
full recovery 
Healthy 
Individuals  
     
6.   Levy,  
2003 [58] 
Low Natural 
Killer T Cells 
Varivax 35 17 days Disseminated 
varicella, full recovery 
7.   Banovic, 
2011 [59] 
Low 
invariant 
Natural 
Killer T Cells 
Varivax   Life-threatening 
disseminated 
varicella 
8.   Bernstein, 
2011 [60] 
Healthy Varivax 27 10 days Vesicular rash, full 
recovery 
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Inactivated VZV Vaccine 
A heat-inactivated zoster vaccine is in development, but to date has not 
shown consistent results regarding its efficacy.  This inactivated VZV vaccine has 
been given to two different groups of immunosuppressed BMT patients in two 
different studies, resulting in two different outcomes.  The first group of BMT 
patients received either one dose of the inactivated VZV vaccine 30 days post-
transplant or two doses, the second 30 days after the first.  A significant increase 
in the mean stimulatory index occurred in both groups approximately 8 weeks 
post-vaccination [61].   However, 1 year later there was no difference in the 
prevalence of HZ reactivation between the vaccinated and the non-vaccinated 
control group, yet the severity of disease was significantly reduced in the 
vaccinated patients [61].  The second group included a heterogeneous group of 
BMT patients that had undergone either allogeneic or autologous hematopoietic-
cell transplantation. The vaccine was found to increase T cell proliferation after 3 
doses spaced 30 days apart, with the first vaccine given prior to transplantation.  
This resulted in a significant decrease in zoster reactivation, conferring a 93% 
protection rate with a stimulation index over 5.0.  While the rate of reactivation 
was decreased, those who developed zoster had no change in the severity of 
disease compared to the non-vaccinated patients [62].  The heat-inactivated VZV 
vaccine was demonstrated to be safe in both studies, but the inconsistent results 
regarding incidence and severity of HZ reactivation suggests that further study of 
the heat-inactivated VZV vaccine is needed. 
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Live Vaccine Safety and Efficacy in the SLE Population 
 Recent reviews have been written in favor of studying the safety and 
efficacy of vaccines to protect the high-risk SLE population from the reactivation 
of HZ [10] [14] [17].  Yet to date, there remains a paucity of data regarding both the 
safety and efficacy of any live attenuated vaccines in SLE patients.  Since there 
has not yet been a single study regarding the SLE population and the shingles 
vaccine, Zostavax, in this section we examine some of the studies done with 
immunocompromised patients and other live vaccines.   
Table 5 summarizes the published data of live-virus vaccinations in 
immunocompromised individuals.  Four disease classifications are listed in Table 
5.  Like SLE patients, all of these patients display some level of 
immunosuppression.  Autoimmune, transplant and malignancy patients all take 
immunosuppressant medications, and autoimmune and transplantation patients 
are usually maintained on immunosuppressive drugs for the duration of their 
lives, leaving them at a relatively high risk for infections and complications 
indefinitely [39].  Individuals with malignancies are treated with high-intensity 
immunosuppressive therapies for periods of time, resulting in intervals of 
severely decreased immune function.  HIV patients are immunocompromised 
due to their disease state, but may be on immune-boosting drugs.  All of these 
individuals have been shown to be at a relatively high risk for the reactivation of 
zoster [10]. 
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 Of the published studies only 3 include the SLE population.  Schattner did 
a retrospective study of SLE patients in Israel who received the Polio vaccine 
during the 1988 Polio outbreak.  One third of patients vaccinated received the 
live attenuated Oral Polio Vaccine (OPV), while the rest were vaccinated with the 
inactivated Injectable Polio Vaccine (IPV).  Neither adverse reactions nor viral-
related disease complications were reported, however, 5% of all vaccinated 
patients developed a lupus flare within 3 months of the vaccination, leading 
Schattner to caution the use of both the OPV and the IPV in the SLE population 
[63].  The second study was a retrospective study done by Mota performed in a 
Yellow Fever endemic area.  The focus of the study was on the rheumatic 
disease population using immunosuppressants who were receiving the Yellow 
Fever vaccination.  Seventy patients were vaccinated against Yellow Fever with 
a live attenuated vaccine, 11 with a diagnosis of SLE [64].  The prevalence of 
adverse reactions in the SLE population was 4.3%, which is not statistically 
different from the the prevelance of adverse reactions among a comparator 
immunocompetent population [64].  The adverse reactions that did occur were 
minor, and no increase in disease activity was reported by visual analog scale or 
SLE disease activity index (SLEDAI) [64].  No vaccine recipients acquired Yellow 
Fever-like illness.  The third study, by Barbosa, appears to be the first example of 
a randomized control study involving SLE patients and a live vaccine.  The 
population study consisted of juvenile SLE patients on a variety of 
immunosuppresants with the exception of corticosteroids >20mg/day or the use 
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of  cyclophosphamide and pulse metylprednisolone three months prior to the 
vaccination [65].  Vaccinated were 28 eligible SLE patients and 28 healthy controls 
with Biken (Varivax, primary VZV vaccination); 27 unvaccinated SLE patients 
were also enrolled as controls [65].  When compared, no significant difference was 
found between the vaccinated and non-vaccinated SLE groups with regard to 
SLEDAI scores and the number of disease flares [65].  During a 2 year follow up, 
15% of unvaccinated patients developed zoster while the frequency of varicella 
and zoster in the vaccinated patients was zero [65].  
 Three very recent studies have been published examining the potential of 
Zostavax in individuals with autoimmune diseases, HIV, and Hematopoietic Stem 
Cell Transplantation/ Hematologic Malignancies HSCT/HM [66] [67] [68].  Zhang 
performed an observational study using administrative claims data evaluating the 
rate of vaccination among subjects with autoimmune diseases receiving 
immunosuppressant therapy.  He found that only 1.6% of patients on 
immunosuppressants were vaccinated.  Among the 551 patients that received 
the vaccine only 1 developed HZ prior to the end of 42-day incubation period of 
the Oka strain; no other adverse events or serious reactions were reported.  This 
suggests that there may not be a significantly increased short-term risk of 
developing vaccine-induced HZ.  The authors also point out that the individuals 
that received the vaccine were selected by their primary care physician as being 
healthy enough to do so, thus they may have been less immunosuppressed or 
had less disease activity [66].  Benson did a randomized, double-blind, placebo-
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controlled (3:1 ZV: placebo) trial in HIV patients aged 18 years and up.  They 
found no significant difference between the incidence of fever or rash post-
vaccination, but did find a significantly higher rate of injection site reactions in the 
experimental group compared to those receiving placebo vaccine as shown in 
Figure 2.  
 
 
 
Percentage of Reactions Post-Vaccination 
 
 
 
 
 
 
Figure 2.  Data from Benson et al. 2012. The figure represents the percentage of 
reactions that occurred after vaccination with either the Zostavax vaccine or a placebo.  No 
significant statistical differences were found between the prevalence of rash or fever in 
vaccine recipients compared to placebo recipients. The only significant difference was 
found when the percentages of injection site reactions were compared.  The group of HIV 
patients that received the Zostavax vaccine had a higher rate of local reactions 
[67]
. 
 
 
 
Placebo in HIV+ Patients Zostavax in HIV+ Patients 
No Adverse Reaction         Injection Site Reaction                 Rash          Fever 
  
Table 5. Studies of Live Vaccines in Immunosuppressed Patients with Different Underlying Diseases 
 
Pediatric =  0-3 years, Child = 4-12, Adolescent = 13-17, Juvenile = 4-17, Adult = 18+,  NR = Not Reported  
RAD = Rheumatic Articular Diseases, HIV = Human Immunodeficiency Virus, IBD = Inflammatory Bowel Disease, BMT = Bone Marrow 
Transplantation, JIA = Juvenile Idiopathic Arthritis, JRD = Juvenile Rheumatic Diseases, ALL = Acute Lymphoblastic Leukemia, SB = 
Small Bowel, HSCT = Hematopoietic Stem Cell Transplant, HM = Hematologic Malignancy.  
Efficacy of 1
o
 vaccine is listed as % of patients that seroconverted.   
Efficacy of Boosters is listed as % of patients with measurable immune response from baseline.   
* = All patients had history of primary varicella, 2 boosters were given 8 weeks a part.  ** Patients were given 2 VZV vaccines 12 weeks 
apart.  *** No statistical difference between patients and healthy controls.  **** A second immunization was given if seroconversion did not 
occur after the first dose.  + Booster given.  != 2 vaccines were given.    
All studies gave one dose of vaccine unless otherwise noted.  All reactions, either local or systemic were mild, transient and treatable with 
acyclovir. 
Author, Year Vaccine Disease Population Safety Efficacy 
 
Auto-immune 
     
1 Yabuuchi, 1984 
[79]
 1⁰ Varicella Non-malignant Pediatric 0.3% developed VZV vaccine-related adverse 
events 
NR 
2 Takahashi, 1986 
[75]
 1⁰ Varicella Non-malignant Children 3% developed mild rash or fever 96% 
3 Schattner, 1992 
[63]
 Polio (OPV 
& IPV)  
SLE <45 years 5% of SLE patients had flares after vaccine NR 
4 Heijstek, 2007 
[80]
 MMR 
Booster 
JIA Juvenile No vaccine-related adverse events NR 
5 Barbosa, 2009 
[65]
 1⁰ Varicella SLE Juvenile *** *** 
6 Borte, 2009 
[76]
 MMR 
Booster 
JIA Juvenile No vaccine-related adverse events *** 
7 Mota, 2009 
[64]
 Yellow 
Fever 
Booster 
SLE Adult *** NR 
8 Lu, 2010 
[71]
 Varicella 
Boosters 
IBD <20 No vaccine-related adverse events 83% 
 
 
     
2
2
 
 
  
 
 
9 Pileggi, 2010 
[72]
 1⁰ Varicella JRD Juvenile 15% developed a rash <12 vesicles *** 
10 Zhang, 2011 
[65]
 Zoster RAD Adult No vaccine-related adverse events NR 
11 Heijstek, 2012 
[81]
 MMR 
Booster 
JIA Juvenile No vaccine-related adverse events NR 
Solid Organ 
 Transplantations 
     
1 Rand, 1993 
[82]
 MMR Liver Children 1 rejection, but no vaccine-related adverse effects 41% 
2 Zamora, 1994 
[83]
 1⁰ Varicella Renal Juvenile 5.8% developed a mild rash 15 days post 65% 
3 Broyer, 1997 
[84]
 **** 1⁰ Varicella Renal Juvenile 1.4% Mild rash <10 vesicles, no systemic reaction 62% 
4 Donati, 2000 
[85]
 1⁰ Varicella Liver Ped/Children No vaccine-related adverse events 27% 
5 Kano, 2002 
[86]
 MMR Liver <17 No vaccine-related adverse events 90.10
% 
 1⁰ Varicella Liver <17 No vaccine-related adverse events 95% 
6 Chaves, 2005 
[87]
 1⁰ Varicella Renal <17 No vaccine-related adverse events 66.60
% 
7 Khan, 2006 
[88]
 1⁰ Varicella Liver <20 8.5%; fever and vesicular rashes at injection site 65% 
 MMR Liver <20 NR 73% 
8 Weinberg, 2006 
[69]
 1⁰ Varicella Liver/SB Children 26% fevers and rashes between days 1-24 87% 
9 Shinjoh, 2008 
[89]
 MMR & 1⁰ 
Varicella 
Liver Children *** 82% 
10 Posfay-Barbe, 2012 
[90]
 1⁰ Varicella Liver Ped/Children 54.8% local and 64.5% systemic reactions 100% 
 
HIV 
     
1   Palumbo, 1992 
[91]
 MMR 
Booster 
HIV Children N/A 64% 
2   Levin, 2001 
[77]
 1⁰ Varicella HIV Children 4.8% rashes papular (not vesicular) 60% 
3   Brady, 2004 
[92]
 Varicella 
Booster 
HIV Adult Minor and uncommon adverse events 85.7% 
 
2
3
 
  
4   Armenian, 2006 
[93]
 1⁰ Varicella HIV Children 30% mild fever, 10% nonvesicular; papule 90% 
5   Bekker, 2006 
[94]
 1⁰ Varicella HIV Children No vaccine-related adverse reactions 60%! 
6   Levin, 2006 
[95]
 1⁰ Varicella HIV Children No vaccine-related adverse events 74% 
7   Gershon, 2009 
[96]
 * Varicella 
Boosters 
HIV Children No vaccine-related adverse events 82%, 
95% 
8   Knorr, 2008 
[97]
 1⁰ Varicella HIV Children No vaccine-related adverse events NR 
9   Weinberg, 2010 
[78]
 Varicella 
Booster 
HIV Adults ***  
10 Taweesith, 2011 
[70]
 ** 1⁰ Varicella HIV Children 5% reported systemic adverse reactions 12%, 
80% 
    < 50 lesions, lasting < 7 days  
11 Benson, 2012 
[67]
 Zoster HIV Adults *** except higher injection site reaction NR 
 
Malignancies 
     
1   Izawa, 1977 
[98]
 1⁰ Varicella Malignancies Children 18% mild rash 3weeks post 100% 
2   Ha, 1980 
[99]
 1⁰ Varicella Leukemia Children 40% had mild fever and popular rashes 96% 
3   Brunell, 1982 
[100]
 1⁰ Varicella Malignancies Children 8.6% biphasic rash 100% 
4   Gershon, 1984 
[101]
 ** 1⁰ Varicella ALL Children Rash in 6% off and 42% on chemo 89% 
 Varicella 
Booster 
ALL Children Rash <10% 95% 
5   Oka, 1984 
[102]
 1⁰ Varicella Leukemia Children 20% with mild fever and rah 100% 
6   Yabuuchi, 1984 
[79]
 1⁰ Varicella Malignancies Children 32.4%  VZV vaccine-related adverse events NR 
7   Haas, 1985 
[103]
 1⁰ Varicella Leukemia Children No vaccine-related adverse events 94% 
 Varicella 
Booster 
Leukemia Children No vaccine-related adverse events 56% 
8   Heller, 1985 
[104]
 1⁰ Varicella Malignancies Children Mild systemic reactions in 21% mild rash in 10% 67% 
9   Ninane, 1985 
[105]
 1⁰ Varicella Leukemia/Soli
d Tumors 
Children 3.2% developed adverse reactions 70% 
10 Slordahl, 1985 
[106]
 1⁰ Varicella Malignancies Children/Adu
lt 
50% developed rashes 75% 
2
4
 
  
 
 
 
11 Takahashi, 1986 
[75]
 1⁰ Varicella Malignancies Children 18.3% had mild VZV reactions(med. Hiatus)  46.8% 
moderate VZV reactions (No med hiatus) 
91% 
12  Heath, 1987 
[107]
 *  1⁰ Varicella Solid Tumors Children 1 developed vesicular rash 5cm diameter 3 
developed mild varicella. 
62%, 
90% 
13  Ljungman, 1989 
[108]
 MMR 
Booster 
BMT Children No vaccine-related adverse events 64% 
14  Arbeter, 1990 
[109]
 1⁰ Varicella Leukemia Children <33% had any adverse reactions 91% 
15  Pauksen, 1992 
[110]
 MMR BMT Children No vaccine-related adverse events 90.4% 
16  Ecevit, 1995 
[111]
 1⁰ Varicella Malignancies Children 28% with mild reactions 95% 
17  LaRussa, 1996 
[112]
 1⁰ Varicella ALL Children 50% on chemo developed a VZV rash 1 month post 82% 
    5% of patients on chemotherapy hiatus dev. Rash  
18   King, 1996 
[113]
 MMR BMT Children No vaccine-related adverse events 68% 
19   Sauerbrei, 1997 
[114]
 1⁰ Varicella BMT Children No vaccine-related adverse events 88.80
% 
20   Morales-Castillo, 
         2000 
[115]
 
1⁰ Varicella Leukemia/Soli
d Tumors 
Children 4.4% with varicellaform rash 90.3% 
21  Machado, 2005 
[116]
 Measles BMT Children No vaccine-related adverse events 100% 
22   Emir, 2006 
[117]
 1⁰ Varicella Lymphoma Ped/Children No vaccine-related adverse events 75% 
 Varicella 
Booster 
Lymphoma Ped/Children No vaccine-related adverse events 50% 
23  Kussmaul, 2010 
[118]
 1⁰ Varicella HSCT Children 2.9% mild reaction, 1.4% moderate reaction 64.3% 
24  Naidus, 2011 
[68]
 Zoster HSCT/HM Adults No vaccine-related adverse events NR 
 
Healthy Controls 
 
 
    
1 Ngai, 1996 
[74]
 1⁰ Varicella N/A Pediatric & 
Children 
11% with fever, 25% with local reaction, 2% with 
cutaneous lesions and 1% with varicellaform rash 
99.9% 
2 White, 1997 
[73]
 1⁰ Varicella N/A Pediatric & 
Children 
14.7% fever, 19.3% local reactions and 3.8% with 
rash 
95% 
2
5
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Naidus retrospectively studied the safety of the Zostavax vaccine in HSCT 
patients who had previously received an autologous or allogeneic HSCT.  Like 
the prior two studies few adverse reactions occurred.  None of the patients 
experienced any vaccine-related adverse reactions [68].  However one patient did 
develop zoster 3 weeks post-vaccination; no tests were done to determine if the 
episode was due to the Oka strain or a wild-type strain [68].  
In general the VZV vaccine has been well tolerated by most individuals,  
both immunocompetent and immunocompromised.  The most common adverse 
reactions reported in these studies were injection site reactions, usually, pain and 
erythema [69] [70].  The most common systemic reactions included headache, 
fever, sore throat and rash.  No serious adverse reactions or rheumatic disease 
flares were observed in the studies regarding the VZV vaccines [70] [71] [72].  
According to a safety and efficacy study done by White, the prevalence of 
adverse events caused by varicella vaccine booster immunizations in the 
immunocompetent, healthy population were: local reactions in 19.3%, fever 
occured in 14.7% and a varicellaform rash occurred at a prevelance of 4% in 
children between ages 1 and 12 [73].  This is in concurance with a previous study 
published by Ngai the prior year [74].  While a few studies listed in Table 5 report a 
higher frequency of adverse reactions, many more of the studies report 
statistically insignificant frequencies of adverse reactions in the 
immunocompromised populations studied. 
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 The range of Ab seroconversion within autoimmune patients vaccinated 
with varicella was 83-96% [71] [75].  Among the healthy population the range of 
seroconversion was from 98.2 to 99.9% [74].   Two of the five studies reported no 
significant statistical difference between the immunogenicity of the vaccine in the 
healthy population compared to the immunogenicity of the vaccine in the 
autoimmune population [65] [76].  The immunogenicity of Varivax was measured by 
the increase in VZV-specific serum Ab titers in these studies.  While the titers for 
SLE patients tend to be lower compared to titers of healthy controls before and 
after vaccinations, the relative increase that occurs is similar. Three of the 
studies listed (Table 5) measured the CMI response to the VZV vaccine with 
different results.  Levin reported CMI responses in HIV-infected children 
measured by Lymphocyte Proliferation Assay (LPA) at 65% and 83% positive 
after the first and second vaccine, respectively.  No correlation between the LPA 
results and titers were found in this HIV group [77].  Weinberg measured CMI by 
LPA in transplant patients and found 86% of patients had a positive response 
after vaccination, and unlike Levin, Weinberg reported striking concordance 
between VZV seroconversion and CMI responses [78].  Barbosa evaluated the 
CMI response in the SLE population by measuring IFN-gamma production by 
ELISpots.  They found lower levels of IFN-gamma production in SLE patients as 
the only significantly different result between the healthy controls and the SLE 
patients when vaccinated with varicella.  No significant differences were seen 
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with respect to the frequency or severity of adverse reactions or with respect to 
the relative increase in VZV-specific titers [78].  
 A handful of studies have been done with SLE patients and live vaccines. 
The results suggest further studies should be done to evaluate the relative 
benefit-to-risk ratio.  The Yellow Fever vaccine was studied in such a small 
sample of SLE patients (n=11) that one cannot assume that the results can be 
generalized to the entire SLE population, but the results were promising.  The 
Polio vaccine was studied in a larger sample of 73 patients but the sample size of 
the group of patients that received the OPV was 24, again a small sample size 
for the two Polio vaccines.  Neither Polio vaccine appeared to be as safe as the 
Yellow Fever vaccine and may have contributed to disease activity [63].  The 
varicella vaccine study had the largest sample size of the three studies, but was 
still relatively small (n=55).  According to the limited published literature to date, it 
appears that the live vaccines tested may be safe and effective in many SLE 
patients. None of the live vaccines mentioned in the literature have caused 
vaccine-related illness as is the fear with using live viral vaccines in 
immunosuppressed patients.  Since all sample sizes were similar, one could 
argue that the vaccines should be studied further in larger sample sizes to truly 
determine the safety of the vaccines.   
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Rationale, Aims and Objectives 
 
There is a general agreement that the increased incidence of HZ seen in 
SLE patients has to do with a change in their immune systems, a change that 
decreases the body’s ability to arrest viral infections at the cellular level.  In 2006 
the Zostavax vaccine was approved for healthy adults 60 years of age and older. 
Then in 2011 it was further approved for healthy adults 50 years and older.  
Zostavax is a live attenuated vaccine, thus concerns have been raised regarding 
the safety of administering the vaccine to individuals with immune dysfunction, 
due to either disease or immunosuppressive therapies.  Our study was designed 
to evaluate the safety and immunogenicity of the Zostavax vaccine in a group of 
SLE patients with mild-moderate disease activity compared to healthy control 
subjects.  
 
 Examine patient records to determine ACR criteria, disease activity via 
SLEDAI, medication usage and laboratory findings such as: total white 
blood cell (WBC) count, renal function, albumin, globulin, proteinuria, 
complement levels and levels of dsDNA antibodies 
 Examine blood samples from each patient and compare CMI responses 
before and after vaccination with Zostavax 
 30 
 
 Peripheral blood mononuclear cells (PBMC) (if available) assayed by 
interferon-gamma releasing ELISpot following stimulation with VZV-
specific Ag, and with phytohemagglutinin (PHA) mitogen activation 
 Evaluate subjects for clinical signs of adverse reactions or changes in 
disease activity due to the Zostavax vaccine  
 
The analyses of these results were evaluated with regard to a change in 
VZV-specific immunity before and after vaccination with Zostavax.  By examining 
the individual’s blood prior to, and at designated points after vaccination, we were 
able to determine whether or not the Zostavax vaccine was able to initiate an 
immune response in SLE patients and how this compares to responses in 
healthy controls.  Physical examinations and patient reports during the study 
period monitored subjects for adverse reactions and increased disease activity 
(in SLE patients).  Determination of adverse events, including injection site 
reactions and levels of disease activity, helped to illustrate the safety of the 
Zostavax vaccine in the SLE population.   
Through the evaluation of these parameters were able to determine if the 
Zostavax vaccine is safe enough to be used in a larger sample and therefore 
better test the safety and efficacy of the Zostavax vaccine in the SLE population. 
This study, while focused on the safety and efficacy of the Zostavax vaccine in 
SLE patients, may also aid in the further understanding of VZV reactivation in 
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both SLE patients and healthy individuals.  It may also increase our knowledge of 
SLE.    
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METHODS 
 
A total of 20 people were included in this study; 10 SLE patients and 10 
healthy controls.  Each of the subjects received a single 0.65-ml dose of 
Zostavax containing a minimum of 19,400 PFUs.  The vaccine was stored, 
administered and disposed of according to the manufacturer’s recommendation.  
Subjects were seen at 0, 2, 6 and 12 weeks to assess adverse events, 
medication changes and SLEDAI scores.  At each interval, peripheral blood was 
sampled and frozen at -80oC for later testing. 
 
Subjects: 
All patients were 50 years of age or older and had serologic evidence of a 
primary VZV infection.  The SLE patients had mild stable disease states with 
clinical SLEDAI scores <4 (excluding dsDNA and complement levels).  
Maintenance medications allowed in this study included: antimalarials, 
methotrexate ≤ 20 mg weekly, azathioprine ≤ 150 mg daily and prednisone ≤ 10 
mg daily. The exclusion criteria included HZ within 5 years of screening, HIV, 
hepatitis B or C, diabetes mellitus along with any uncontrolled hepatic, renal, 
hematologic or CNS disease.  Medications that were not acceptable included:  
mycophenolate mofetil, cyclophosphamide or any biologic agent.   
Ten SLE patients and 10 healthy controls were seen on day 1 of the study 
to receive the vaccine and have approximately 65 cc of peripheral blood drawn.  
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Follow up visits were scheduled at 2, 6 and 12 weeks; on each day an additional 
65 cc of peripheral blood was drawn. 
Approximately 15 cc of blood was sent to be monitored for safety and 
clinical disease activity to laboratories for: CBC, CMP, urinalysis, urine HCG (if 
applicable), and (for SLE patients only) dsDNA Ab, complement C3 and C4 
levels.  The remaining blood (approximately 50 cc) was then frozen at -80oC until 
samples from all visits were obtained.  PBMCs were obtained from the remaining 
peripheral blood and batched for analysis of VZV-specific immune responses.   
 
ELISpot Protocol: 
Interferon-gamma enzyme-linked immunosorbent spot (IFN-γ ELISpot) 
assays were performed using previously frozen (-80oC) PBMCs as described 
previously [119].  Cells were washed and resuspended in Roswell Park Memorial 
Institute (RPMI) 1640 media with 10% Fetal Bovine Serum (FBS), 1% penicillin-
streptomycin, and 1% L-glutamine w/ 10 mM (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES).  The Vero cell line is used for the 
propagation of the VZV, and thus was used as a negative control.  A working 
solution of 60ug/ml was made and 100ul was added to each well for a final 
concentration of 30ug/ml to each experimental control well.  The VZV antigen 
(VZV rod strain; an inactivated cell extract of the Varicella-Zoster Virus) was used 
as a working solution with a concentration of 60ug/ml from the stock solution 
(0.7mg/ml).  Again 100ul of the working solution was added to the appropriate 
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well to get a final concentration of 30ug/ml in each well.  The frequency of spot 
forming cells (SFCs) were then obtained with an automatic plate reader and 
expressed per 10^5 PBMCs. 
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RESULTS 
 
Demographics 
The demographics of the study participants are listed in Table 6.  There 
were no statistically significant differences between groups.  All enrolled subjects 
were women, and all were >50 years old.  The average age of participants was 
57.9 years of age, with SLE patients being slightly older than healthy controls 
(60.5 and 55.3 years, respectively).  African Americans accounted for 30% of 
individuals in the study and European Americans the other 70%. 
 
 
 
 
 
 
Table 6.           Demographics of Study Participants at Baseline 
 
 SLE Healthy 
N 10 10 
Age, mean (SD) 60.5 (5.4) 55.3 (4.2) 
Race: 
   European American 
 
7 
 
7 
   African American 3 3 
History of Shingles 4 2 
Medications 
   Prednisone (N) 
 
4 
 
- 
   Hydroxychloroquine 
   Methotrexate 
7 
2 
- 
- 
SLEDAI, mean (SD)  1.1 (0.99) - 
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SLEDAI 
As seen in Figure 3, the average SLEDAI score prior to vaccination was 
1.1 with an average change 6 weeks after vaccination of 0.2.  The change in the 
average SLEDAI score was not statistically significant and no SLE disease flares 
occurred during the length of the study.  All SLEDAI scores remained lower than 
4 throughout the course of the study.  
 
 
 
 
 
 
 
Figure 3. The mean SLEDAI scores and ranges are depicted.  The 
highest mean values were at week 6 and prior to vaccination.  None were 
found to be significantly different from the other data points. 
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Anti-dsDNA Antibodies 
While two SLE patients had a slight increase in the amount of dsDNA 
being produced there was no consistent trend indicating an increase of dsDNA 
within the SLE group.  No significant difference was found between the average 
levels of dsDNA (in SLE patients) at different time points (data not shown).    
 
Safety 
None of the patients or controls exhibited any signs of zoster during the 
study interval.  No vesicular lesions were seen at the injection site or otherwise, 
and no systemic reactions such as fever were reported.  There were no serious 
adverse reactions to the vaccine in either study group.  No cases of HZ occurred 
in either the SLE patients or the controls (Table 7).   
No significant difference was found between the numbers of individuals 
with injection site reactions, nor was there a difference in the severity of reactions 
that occurred, in healthy controls when compared to SLE patients.  Erythema and 
tenderness were the most commonly reported injection site reactions in both the 
experimental and control groups, reactions that are often seen with any 
subcutaneous injection or vaccination.   
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Table 7.    Safety Outcomes in SLE and Healthy Subjects. 
ISR = Injection site reaction.  Week 6 SLEDAI given as mean (SD).  All other 
values are given as number of individuals.  No significant differences were found. 
 
 SLE Healthy 
N 10 10 
ISR 3 3 
Erythema, tenderness 3 3 
Vesicular 0 0 
6 week SLEDAI 1.3 (1.2)  
SLE flares 0  
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Immunogenicity: 
ELISpot: VZV and Phytohemagglutinin (PHA) 
Figure 4 shows the average number of SFCs stimulated by VZV-specific 
Ag.  A significant difference was found (P=0.03) between the mean number of 
SFCs of the SLE group and the healthy control group at week 6.  SLE patients 
had a significantly lower number of SFCs compared to healthy controls.  No other 
significant difference was found between the average numbers of SFCs of SLE 
patients and healthy controls at the baseline, week 2 or week 12.     
 
 
 
 
Figure 4. VZV-specific cells from peripheral blood and by ELISpot.  A 
significant difference was found between SLE patients and healthy controls in 
week 6; SLE patients had significantly lower numbers.  No other significant 
difference was found. 
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The average numbers of PHA, mitogen-stimulated T cells, are shown in 
Figure 5.  No significant differences were found between the SLE and the healthy 
controls at baseline, 2, 6 or 12 weeks.  Although it did not reach significance, 
there was a similar decrease in the average number of SFCs at week 6 when 
stimulated with PHA, as there was when stimulated by VZV-specific Ag.  
 
 
 
 
Figure 5. Cell counts stimulated by PHA in peripheral blood.  While SLE 
patients consistently had lower mean levels of stimulatory cell, no statistical 
difference was found. 
 
 41 
 
DISCUSSION: 
 
To date there is a dearth of published literature regarding SLE and live 
vaccines, and there appears to be no published work regarding SLE and the live 
attenuated HZ vaccine, Zostavax.  Approximately 98% of the adult population 
has been exposed to primary varicella, and thus, carries the risk of reactivation 
[121].  To date, the Zostavax vaccine has been approved for use in healthy adults 
aged 50 years and older.  However, the majority of SLE patients are diagnosed 
in their fourth decade of life, well before it is appropriate for them to receive the 
Zostavax vaccine.  Once diagnosed with SLE, patients begin a life-long regime of 
immunosuppressive therapy – meaning that once SLE patients reach 50 years of 
age they are still ineligible to receive the Zostavax vaccine that could protect 
them from HZ reactivation.  
When SLE is diagnosed it may be imperative that treatment begin 
immediately to decrease disease activity and prevent organ damage.  
Suspended or discontinued treatment regimes may lead to SLE flares and further 
complications like vasculitis or nephritis.  This suggests that SLE patients may 
not be able to delay treatment or take a drug vacation for the purpose of 
receiving a vaccine, like Zostavax.  For this reason we studied the vaccination of 
mild-moderately immunosuppressed individuals against HZ. 
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SLE patients have not been vaccinated in the past due to two serious 
concerns: the risk of causing a vaccine-related illness and the risk of 
exasperating SLE.  In this study there was no evidence of either.  
 
Clinical 
Supporting evidence includes the lack of increase in SLEDAI scores. 
SLEDAI scores are indicative of the overall physical well being of a patient.  The 
score includes 16 clinical criteria: seizure, psychosis, organic brain syndrome, 
visual disturbance, other neurological problems, hair loss, rash, muscle 
weakness, arthritis, blood vessel inflammation, mouth sores, chest pain worse 
with deep breathing and manifestations of pleurisy and/or pericarditis and fever.  
The SLEDAI also includes eight laboratory criteria: proteinuria, low blood 
complement levels, increased anti-DNA Ab levels, low platelets, and low WBC 
count.   The Zostavax vaccine did not appear to induce any adverse changes in 
the above listed criteria. 
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Immunogenicity 
It has been shown that SLE patients express less of an immune response 
to vaccines compared to healthy controls.  It has not been confirmed whether the 
decrease in immune response is due to immunosuppressive treatment alone, or 
if SLE disease activity plays a role, although this does seem to be the case.    
Either way it does appear that SLE patients are able to elicit an immune 
response to the Zostavax vaccine.  While the threshold for immunity has not 
been determined yet, the ability of the vaccine to stimulate CMI is an indication 
that the vaccine may help reduce the risk of HZ in SLE patients.  Further studies 
should be conducted regarding the CMI response to live vaccines, especially the 
zoster vaccine, and its effectiveness in reducing the incidence of HZ in SLE 
patients.   
The results of this study are promising, but not conclusive.  While all of the 
results indicate that the Zostavax vaccine may be safe in the SLE population,  
the sample size of this study was too small to make any generalizations. The 
results obtained in this small sample may not be a good representation of the 
SLE population with mild to moderate disease.   
Further, the freezing of peripheral blood samples and storage at -80oC 
until batched for analysis presents an interesting issue.  Frozen samples have 
been shown to have a decrease in viable cell counts [119].  Thus the degree of 
CMI responses that were seen in either of the ELISpot assays may have been 
diminished by the storing process.  While both the healthy control samples and 
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the SLE samples were treated the same and thus the relative differences should 
not be affected, a future study done with fresh samples may give a better 
representation of the elicited CMI response in both groups. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 45 
 
Summary: 
The Zostavax vaccine was shown to be safe and elicited an immune 
response from SLE patients in this small sample.  Almost all of the results were 
not statistically different from the results obtained from healthy controls, with the 
exception of the 6-week results of the ELISpot VZV-specific stimulated cells.  A 
significant difference was found (P=0.03) between SLE patients and healthy 
controls with regards to the number of SFCs.  The mean number of SFCs in SLE 
patients was significantly lower compared to the number of SFCs of healthy 
controls.  No vaccine-induced illness was evident and there was no sign of an 
increase in SLE disease activity in patients.  
Future study directions should include evaluation of individuals at a 
relatively high risk.  In this case, increasing IRs, increased numbers of risk 
factors, and an increase in average prevalence of HZ  along with a decrease in 
average age of presentation make SLE patients prime candidates for the study of 
HZ prevention by vaccination.  In addition, the rare occurrence of disease caused 
by the Oka strain of VZV has been easily resolved compared to the wild-type 
strains of VZV.   
The Zostavax vaccine should also be studied in younger individuals and 
individuals on different drug regimes to determine the best way to vaccinate SLE 
patients with Zostavax.  The inactivated VZV vaccine should be checked for the 
elicitation of VZV-specific CMI responses.  Quantification of diminishing CMI 
responses and subsequent booster schedules should be put into practice. 
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Studies focused on administration of the VZV vaccine prior to 
immunosuppression should be conducted to determine if the immunity provided 
by the vaccine carries over.  In short, optimizing the immunogenicity and safety 
of the live VZV vaccine in SLE patients could greatly increase QALY in SLE 
patients and reduce the treatment costs of HZ for SLE patients.  This study may 
pave the way for a larger safety and immunogenicity study to better determine 
the risks and benefits of vaccinating SLE patients with the Zostavax vaccine. 
In many cases the reactivation of HZ in the SLE population is benign and 
non-life threatening, but on occasion severe cases and complications have been 
reported [16].   It is important for these patients to be protected from preventable 
diseases to decrease the chance of further complications – due to either the 
worsening of disease activity or infection.  The aim of vaccination is to lower the 
risk for “uncomplicated” HZ in SLE patients and to decrease the significant 
morbidity associated with HZ,  subsequently decreasing PHN and other more 
serious manifestations of HZ [122]. 
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